ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Study Comparing the Safety and Efficacy of Two Doses of BC-3781 vs Vancomycin in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)

ClinicalTrials.gov ID: NCT01119105

Public ClinicalTrials.gov record NCT01119105. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 19, 2026, 7:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II, Multi-center, Randomized, Double-blind Study Comparing the Safety and Efficacy of Two Doses of BC-3781 Versus Vancomycin in Patients With Acute Bacterial Skin and Skin Structure Infection

Study identification

NCT ID
NCT01119105
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Nabriva Therapeutics AG
Industry
Enrollment
210 participants

Conditions and interventions

Interventions

  • BC-3781 Drug
  • Vancomycin Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 30, 2010
Primary completion
Dec 30, 2010
Completion
Feb 2, 2011
Last update posted
Nov 16, 2020

2010 – 2011

United States locations

U.S. sites
9
U.S. states
5
U.S. cities
9
Facility City State ZIP Site status
BC-3781 Study Center 002 Chula Vista California 91911
BC-3781 Study Center 001 La Mesa California 91942
BC-3781 Study Center 003 Oceanside California 92056
BC-3781 Study Center 012 Columbus Georgia 31904
BC-3781 Study Center 018 Savannah Georgia 31406
BC-3781 Study Center 021 Baton Rouge Louisiana 70808
BC-3781 Study Center 023 Lafayette Louisiana 70503
BC-3781 Study Center 004 Butte Montana 59701
BC-3781 Study Center 016 Somers Point New Jersey 08244

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01119105, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 16, 2020 · Synced May 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01119105 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →